- Home
- SGLY vs APVO Comparison
SGLY vs APVO Comparison
Compare SGLY & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- APVO
- Stock Information
- Founded
- SGLY 2001
- APVO 2016
- Country
- SGLY United States
- APVO United States
- Employees
- SGLY N/A
- APVO N/A
- Industry
- SGLY
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- APVO Health Care
- Exchange
- SGLY Nasdaq
- APVO Nasdaq
- Market Cap
- SGLY 4.4M
- APVO 4.1M
- IPO Year
- SGLY 2008
- APVO N/A
- Fundamental
- Price
- SGLY $1.05
- APVO $2.94
- Analyst Decision
- SGLY
- APVO Strong Buy
- Analyst Count
- SGLY 0
- APVO 1
- Target Price
- SGLY N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- SGLY 42.6K
- APVO 179.3K
- Earning Date
- SGLY 08-26-2025
- APVO 08-07-2025
- Dividend Yield
- SGLY N/A
- APVO N/A
- EPS Growth
- SGLY N/A
- APVO N/A
- EPS
- SGLY N/A
- APVO N/A
- Revenue
- SGLY $2,172,036.00
- APVO N/A
- Revenue This Year
- SGLY N/A
- APVO N/A
- Revenue Next Year
- SGLY N/A
- APVO N/A
- P/E Ratio
- SGLY N/A
- APVO N/A
- Revenue Growth
- SGLY N/A
- APVO N/A
- 52 Week Low
- SGLY $0.54
- APVO $2.81
- 52 Week High
- SGLY $7.65
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- SGLY 51.17
- APVO 36.47
- Support Level
- SGLY $0.99
- APVO $3.01
- Resistance Level
- SGLY $1.14
- APVO $3.18
- Average True Range (ATR)
- SGLY 0.05
- APVO 0.16
- MACD
- SGLY 0.00
- APVO 0.17
- Stochastic Oscillator
- SGLY 57.14
- APVO 18.18
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.